Valeant Pharma (VRX) Posts Mixed Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
February 28, 2018 7:00 AM ESTLAVAL, Quebec, Feb. 28, 2018 /PRNewswire/ --
Fourth-Quarter 2017 Financial Results Revenues of $2.163 Billion GAAP Net Income of $513 Million GAAP Cash Flow from Operations of $578 Million Adjusted EBITDA (non-GAAP)1 of $875 Million Full-Year 2017 Financial Results Revenues of $8.724 Billion GAAP Net Income of $2.404 Billion GAAP Cash Flow from Operations of $2.290 Billion Adjusted EBITDA (non-GAAP) of $3.638 BillionValeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:... More
